Eli Lilly

News

After so many announcements of new facility builds in the US, Eli Lilly has made a welcome commitment to a European investment.

News

Eli Lilly is celebrating a massive 54% increase in its third-quarter revenues to $17.6 billion, driven by its medicines for diabetes and obesity.

News

Eli Lilly and NVIDIA have joined forces on an ambitious plan – building pharma's most powerful AI-powered supercomputer for drug discovery.

News

Innovent's dual glucagon and GLP-1 agonist mazdutide outperforms Novo Nordisk's Ozempic in overweight people with diabetes.

News

Eli Lilly has revealed long-term follow-up data with adjuvant Verzenio in early breast cancer, including a 15.8% improvement in survival.

News

Eli Lilly has built the case for its oral GLP-1 orforglipron with two more phase 3 readouts, including a head-to-head win over Farxiga in diabetes.